Exosome-Mediated Transfer of miR-3613-5p Enhances Doxorubicin Resistance by Suppression of PTEN Expression in Breast Cancer Cells

Figure 3

Exosome-mediated miR-3613-5p transfer enhances the resistance of breast cancer cells to doxorubicin. (a) qRT-PCR was used to assess the relative level of miR-3613-5p in MCF-7 and MDA-MB-231 cells after incubation with exosomes isolated from doxorubicin-resistant cells (EXO) and with the treatments of NC inhibitor (NC inhibitor-EXO) or miR-3613-5p inhibitor (miR-3613-5p inhibitor-EXO). . Data are of 3 independent experiments. (b) CCK8 was used to assess cell viability of MCF-7 and MDA-MB-231 cells after the treatments of PBS, EXO, NC inhibitor-EXO, or miR-3613-5p inhibitor-EXO. (Upper and middle) Curve of cell viability after indicated treatments in MCF-7 and MDA-MB-231 cells. (Lower) Half maximal inhibitory concentration (IC₅₀) values of doxorubicin (DOX) in MCF-7 and MDA-MB-231 cells. . Data are of 3 independent experiments. (c) Crystal violet staining to detect colony formation of MCF-7 and MDA-MB-231 cells after the cells treated with 20 μM DOX combined with treatments of PBS, EXO, NC inhibitor-EXO, or miR-3613-5p inhibitor-EXO. (d) Colony forming area (%) detected by crystal violet staining in (c). , . Data are of 3 independent experiments. (e, f) Flow cytometry was used to detect the cell apoptosis rate of MCF-7 and MDA-MB-231 cells after the cells treated with 20 μM DOX combined with treatment of PBS, EXO, NC inhibitor-EXO, or miR-3613-5p inhibitor-EXO. . Data are of 3 independent experiments.

(a)

(b)

(c)

(d)

(e)

(f)